Publication: Diseño de nuevos fármacos y nuevas dianas frente al mycobacterium tuberculosis
Loading...
Official URL
Full text at PDC
Publication Date
2017-06
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Citations
Exportar
Abstract
La tuberculosis es, hoy día, una amenaza para la salud en todo el mundo. A medida que las cepas de Mycobacterium tuberculosis han ido surgiendo y se han transformado en cepas resistentes, el fracaso del tratamiento es con demasiada frecuencia un hecho, especialmente en aquellos países que carecen de la organización de atención médica necesaria para proporcionar el largo y costoso tratamiento. Debido a esta preocupación, esta enfermedad infecciosa ha sido el foco de interés científico en la última década. A pesar de los avances en la quimioterapia y la vacuna BCG (Bacillus Calmette-Guérin), la tuberculosis sigue siendo una enfermedad infecciosa significativa. La capacidad de los bacilos de tuberculosis para causar infecciones latentes que son tolerantes con los fármacos usados actualmente, junto con la dosis inadecuada y los regímenes de tratamiento incompleto han llevado al aumento de la tuberculosis multirresistente (MDRTB). El tratamiento de las infecciones por MDR-TB es un reto clínico importante que tiene pocas soluciones viables o eficaces, por lo tanto, los pacientes tienen un mal pronóstico y años de tratamiento. La aparición creciente de la tuberculosis resistente a los fármacos y la infección por el VIH, que compromete la defensa del huésped y permite que la infección latente reactive o vuelva a los individuos más susceptibles a la tuberculosis, ponen en relieve la necesidad de desarrollar nuevos fármacos contra la tuberculosis activos contra las bacterias resistentes a los fármacos. Los recientes y novedosos desarrollos en el descubrimiento de fármacos para la tuberculosis con una dosificación más larga o que pueden reducir la duración del tratamiento muestran ser prometedores hacia una posible revolución en la quimioterapia de la tuberculosis.
Tuberculosis is one of the main threats for health worldwide nowadays. As resistant strains of Mycobacterium tuberculosis have slowly emerged, the failure of treatment is sadly too often a fact, especially in countries lacking the necessary health care organization to provide the long and costly treatment have adapted by the patients. Due to this concern, this infectious disease was the focus of renewed scientific interest in the last decade. Mycobacterium tuberculosis A. Fernández Gil y R. García Mayoral 4 Despite advances in chemotherapy and the BCG (Bacillus Calmette–Guérin) vaccine, tuberculosis remains significant infectious disease. Bacillus’ capacity to cause latent infections which are resistant to common drugs in addition to inaccurate dosages and incomplete treatments have led to an increase in multirresistant-tuberculosis (MDR-TB). An effective treatment for this sort of infections is a huge challenge as it relies on very few effective solutions. As a result of the previous, treatments last extremely long and patients’ prognosis is not favourable. The increasing emergence of drug resistance in combination with AIDS, which endangers host’s health and allows reactivation of persistent infection highlight the need to develop novel TB drugs that are active against drug resistant bacteria but, more importantly, kill persistent bacteria and shorten the length of treatment. Recent new and exciting developments in tuberculosis drug discovery show good promise of a possible revolution in the chemotherapy of tuberculosis.
Tuberculosis is one of the main threats for health worldwide nowadays. As resistant strains of Mycobacterium tuberculosis have slowly emerged, the failure of treatment is sadly too often a fact, especially in countries lacking the necessary health care organization to provide the long and costly treatment have adapted by the patients. Due to this concern, this infectious disease was the focus of renewed scientific interest in the last decade. Mycobacterium tuberculosis A. Fernández Gil y R. García Mayoral 4 Despite advances in chemotherapy and the BCG (Bacillus Calmette–Guérin) vaccine, tuberculosis remains significant infectious disease. Bacillus’ capacity to cause latent infections which are resistant to common drugs in addition to inaccurate dosages and incomplete treatments have led to an increase in multirresistant-tuberculosis (MDR-TB). An effective treatment for this sort of infections is a huge challenge as it relies on very few effective solutions. As a result of the previous, treatments last extremely long and patients’ prognosis is not favourable. The increasing emergence of drug resistance in combination with AIDS, which endangers host’s health and allows reactivation of persistent infection highlight the need to develop novel TB drugs that are active against drug resistant bacteria but, more importantly, kill persistent bacteria and shorten the length of treatment. Recent new and exciting developments in tuberculosis drug discovery show good promise of a possible revolution in the chemotherapy of tuberculosis.